Page 6 - PHESGO (PERTUZUMAB-TRASTUZUMAB) - Product Monograph

2. UNMET MEDICAL NEED IN HER2-POSITIVE BC

2.1. Intravenous (IV) HER2+ cancer care offers the results patients need -
but at what costs?

 Treatment with IV PERJETA (P)+ Herceptin (H) has proven benefits in HER2+
®
®
BC, for adjuvant, neoadjuvant and metastatic settings. 28-34
 However, many patients still receive this dual HER2-blockade via IV, requiring
up to 9.5 hours - an entire day - of patient and staff time to be spent in the
IV suite. 35,36

Loading doses (max)
P + H IV 150 420

P + H IV infusion
Maintainence doses 90 180
(max) Observation time
P + H IV
0 40 80 120 160 200 240 280 320 360 400 440 480 520 560 600
Time (minutes)

 IV preparation can also take up to 22 minutes per treatment given, potentially

occupying pharmacy staff for almost 45 minutes per dual blockade session. 37
 These demands on time and resources impact not only treatment capacity but
also staff wellbeing, with high workload cited as a major cause of stress and poor
mental health. 37

2.2. IV HER2+ cancer care is effective but time-consuming

 Every appointment for IV HER2+ cancer care can require up to 40 minutes of
active HCP time involving oncologists, nurses, pharmacists and pharmacy staff. 37

 Drug preparation can account for up to 50% of this time, almost as much as
drug initiation and observation combined. 37

Active HCP time in the treatment room and drug preparation area per session 37

13.9 minutes Observed time in drug preparation area

17.9 minutes Observed time in treatment room

M-AE-00000086 6